Modeling De Novo Leukemogenesis from Human Cord Blood with MN1 and NUP98HOXD13
Co-transduction of an activated HOX gene with MN1 induces a serially transplantable acute myeloid leukemia (AML). Further characterization of the leukemic cells generated from the dually transduced cells revealed activation of stem cell gene expression signatures also found in primary human AML. [Blood] Abstract
HIF-1alpha Regulates mTOR Signaling and Viability of Prostate Cancer Stem Cells
A well characterized murine model of prostate cancer was used to investigate the regulation of hypoxia-inducible factor 1alpha (HIF-1alpha) in cancer stem cells and a basal stem cell subpopulation was identified, in primary prostate tumors of mice, with elevated HIF-1alpha expression. [Mol Cancer Res] Abstract
miR-99a Directly Targets the mTOR Signaling Pathway in Breast Cancer Side Population Cells
Scientists detected expression of miR-99a in the side population (SP) cells compared to non-SP cells using real-time PCR, and explored effects of miR-99a on the cancer stem cell phenotype of the breast cancer cells, including sphere formation, self-renewal, tumorigenicity and cell migratory capability. [Cell Prolif] Abstract
Crosstalk between CTC, Immune System and Hypoxic Tumor Microenvironment
The authors discuss how hypoxia is involved in the regulation of tumor progression and induction of EMT and cancer stem cell like features. They also illustrate the relationship between hypoxia and circulating tumor cells (CTC) and review how CTC interact with the cells of immune system in terms of their survival and EMT phenotype. [Cancer Microenviron] Abstract
Visit our reviews page to see a complete list of reviews in the cancer stem cell research field.
Synta Announces Initiation of I-SPY 2 TRIAL of Ganetespib in Breast Cancer
Synta Pharmaceuticals Corp. announced the initiation of the I-SPY 2 TRIAL (Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging And moLecular Analysis 2) arm evaluating ganetespib, the company’s Hsp90 inhibitor, as a neoadjuvant therapy for patients with breast cancer. [Synta Pharmaceuticals Corp.] Press Release
Merck Receives FDA Breakthrough Therapy Designation for KEYTRUDA® (Pembrolizumab) in Advanced Non-Small Cell Lung Cancer
Merck announced that the U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to KEYTRUDA®, the company’s anti-PD-1 therapy, for the treatment of patients with epidermal growth factor receptor mutation-negative, and anaplastic lymphoma kinase rearrangement-negative non-small cell lung cancer whose disease has progressed on or following platinum-based chemotherapy. [Merck & Co., Inc.] Press Release
Recruit Top Talent: Reach more than 50,000 potential candidates by posting
your organization’s career opportunities on the Connexon Creative Job Board at no cost.
Have we missed an important article or publication in Cancer Stem Cell News? Click here to submit!
![[Watch the Video] Detect Cancer Stem Cells with ALDEFLUOR™.](https://img.en25.com/eloquaimages/clients/StemcellTechnologiesInc/{dbb756c3-bde3-45ac-ac59-8b828eddf00b}_ON393-VerB-Aldefluor_quickvid_645x110.jpg)
